Deep learning-based assessment of PD-L1 expression in NSCLC predicts outcome for patients treated with anti-PD-1 immunotherapy

BackgroundPD-L1 expression is widely used as a predictive biomarker for anti-PD-1 therapies in non-small cell lung cancer (NSCLC). However, its prognostic value remains controversial. Here, we investigated whether deep learning (DL) applied to PD-L1 immunohistochemistry (IHC) slides could identify h...

Descripción completa

Detalles Bibliográficos

Autores principales:	Morgane Peroz, Nicolas Roussot, Alis Ilie, David Rageot, Valentin Derangere, Caroline Truntzer, François Ghiringhelli
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2026-02-01
Colección:	Frontiers in Immunology
Materias:	biomarker deep learning - artificial intelligence histopathalogical lung predictive model
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1750816/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!